7152-75-2

Basic information

• Product Name: 4-(4-nitrobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one
• CAS NO: 7152-75-2
• Molecular Formula: C₁₆H₁₀N₂O₄
• Molecular Weight: 294.2616
• Mol File: 7152-75-2.mol
• Article Data: 60

Chemical Properties

• Boiling Point: 436.8°C at 760 mmHg
• Flash Point: 218°C
• Density: 1.34g/cm³
• Vapor Pressure: 7.86E-08mmHg at 25°C
• Refractive Index: 1.648
• CAS DataBase Reference: 4-(4-nitrobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-nitrobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one(7152-75-2)
• EPA Substance Registry System: 4-(4-nitrobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one(7152-75-2)

Safety Data

• Hazardous Substances Data: 7152-75-2(Hazardous Substances Data)

Upstream product

• 495-69-2 Hippuric Acid 
• 555-16-8 4-nitrobenzaldehdye 
• 98184-34-0 2-phenyl-5-oxo-4,5-dihydrooxazol-4-idenetriphenylphosphorane 
• 70615-80-4 2-phenyl-5-thioxo-4,5-dihydrooxazol-4-idenetriphenylphosphorane 
• 19185-38-7 2-benzoylamino-3-hydroxy-3-(4-nitrophenyl)propionic acid ethyl ester 
• 1199-01-5 2-phenylazlactone 
• 108-24-7 acetic anhydride 
• 41468-11-5 sodium hydroxy(4-nitrophenyl)methanesulfonate 
• 619-73-8 4-nitrobenzyl chloride 
• 98-88-4 benzoyl chloride 
• 532-94-5 sodium hippurate 

Downstream Products

• 84019-96-5 4-((Z)-4-amino-benzylidene)-2-phenyl-4H-oxazol-5-one 
• 93634-60-7 (Z)-ethyl 2-benzamido-3-(4-nitrophenyl)acrylate 
• 2922-41-0 (p-aminophenyl)alanine 
• 93634-58-3 2-benzoylamino-3-(4-nitrophenyl)acrylic acid 
• 1738-45-0 3-(4-nitro-phenyl)-2-(5-phenyl-tetrazol-1-yl)-acrylic acid 
• 95161-07-2 4-(4-nitro-benzhydryl)-2-phenyl-4H-oxazol-5-one 
• 136712-99-7 3-(1H-Benzoimidazol-2-ylamino)-5-[1-(4-nitro-phenyl)-meth-(Z)-ylidene]-2-phenyl-3,5-dihydro-imidazol-4-one 
• 136713-07-0 3-(Benzooxazol-2-ylamino)-5-[1-(4-nitro-phenyl)-meth-(Z)-ylidene]-2-phenyl-3,5-dihydro-imidazol-4-one 
• 91020-83-6 N-{(Z)-2-(4-Nitro-phenyl)-1-[N'-(2-phenyl-quinazolin-4-yl)-hydrazinocarbonyl]-vinyl}-benzamide 
• 84546-60-1 6-Bromo-2-methyl-3-(4-{4-[1-(4-nitro-phenyl)-meth-(Z)-ylidene]-5-oxo-2-phenyl-4,5-dihydro-imidazol-1-yl}-phenyl)-3H-quinazolin-4-one 
• 19655-74-4 α-benzoylamino-4-nitro-cinnamic acid hydrazide 
• 39784-24-2 4-(4-nitrobenzylidene)-2-phenyl-2-imidazolin-5-one 
• 136949-28-5 2-Amino-5-[1-(4-nitro-phenyl)-meth-(Z)-ylidene]-3,5-dihydro-imidazol-4-one 
• 105707-19-5 ethyl cis-2-methyl-4-(4-nitrophenyl)-6-oxo-5-[(phenylcarbonyl)amino]-1,4,5,6-tetrahydropyridine-3-carboxylate 

Relevant articles and documents

Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone-based benzenesulfonamides

New imidazolinone-based benzenesulfonamides 3a–e and 4a–e were synthesized in three steps?and their chemical structures were confirmed by 1H NMR (nuclear magnetic resonance), 13C NMR, and high-resolution mass spectrometry. The benzenesulfonamides used were sulfacetamide (3a, 4a), sulfaguanidine (3b, 4b), sulfanilamide (3c, 4c), sulfadiazine (3d, 4d), sulfamerazine (3e), and sulfathiazole (4e). The compounds were evaluated against carbonic anhydrase (CA) and acetylcholinesterase (AChE) enzymes to obtain possible drug candidate/s. The lead compounds of the series were 3a and 4a against human CA (hCA) I, whereas?3d and 4a were leads against hCA II in terms of Ki values. Series 4 includes more effective CAs inhibitors than series 3 (except 3d). Series 4 compounds having a nitro group (except 4d) were 3.3–4.8 times more selective inhibitors than their corresponding analogues 3a–d in series 3, in which hydrogen was located in place of the nitro group, by considering Ki values against hCA II. Compounds 3c and 4c, where the sulfanilamide moiety is available, were the leads in terms of AChE inhibition with the lowest Ki values. The use of secondary sulfonamides was a more effective modification on CA inhibition, whereas the primary sulfonamide was the effective substitution in terms of AChE inhibitory potency.

Discovery of a necroptosis inhibitor improving dopaminergic neuronal loss after mptp exposure in mice

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, mainly characterized by motor deficits correlated with progressive dopaminergic neuronal loss in the substantia nigra pars compacta (SN). Necroptosis is a caspase-independent f

Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity

Inhibitors of carbonic anhydrase (CAIs) hold promise for addressing various diseases, including cancer, diabetes, and other metabolic syndromes. CAV is the only isoform present in the mitochondria and is considered a potential drug target for obesity. In